Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) today announced positive topline results for the Phase 3 V ...
FDA has provided input on key elements of the SER-155 allo-HSCT clinical development plans including support for the proposed primary efficacy ...
Free-speech battles and pressure from Washington threaten America’s oldest university—and the soul of higher education.
Search the most accurate and complete listings in the industry. Get an online offer in 2 minutes using our Sell My Car tool.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback